Navigation Links
NeurogesX CEO Anthony DiTonno to Retire by Year End

SAN MATEO, Calif., April 29, 2011 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced that long time CEO Anthony DiTonno will retire by December 31, 2011. The Board of Directors has initiated a formal executive search for a Chief Executive Officer.

Anthony DiTonno commented, "I have been CEO of NeurogesX for more than eight years and we have accomplished the objectives I established for myself when I joined the Company in March 2003. It has been my privilege to work with my colleagues at NeurogesX to take Qutenza through all phases of clinical development and regulatory approvals throughout the world resulting in the successful launch of Qutenza in the United States by our sales team and with our partner Astellas in Europe, the Middle East and Africa. Our focus on finding a replacement will be to find someone with the appropriate commercial and business experience to take the Company to the next level. As we enter our second full year of commercialization, the timing is ideal for this transition to lead this great company into the future. Decisions like this are difficult and I cannot overstate my enthusiasm for Qutenza and NeurogesX going forward."

Jean-Jacques Bienaime commented, "The Board of Directors thanks Tony for his vision, leadership and tenacity during his tenure as CEO. We are pleased that he has agreed to continue to lead the Company up to the end of the year to assure a smooth transition of leadership."

Mr. Bienaime continued, "At the same time, we are excited to have Gary Lyons join our board. Gary has extensive biotech experience and demonstrated success in commercial, business development and financing, which I believe will benefit the Company greatly."

Gary A. Lyons served as a director of Neurocrine Biosciences since February 1993 and also served as the Company's President and Chief Executive Officer from February 1993 through January 2008. Previously, Mr. Lyons held a number of senior management positions at Genentech, Inc. including Vice President of Business Development and Vice President of Sales, and had operating responsibility at Genentech Canada and Genentech Japan. Mr. Lyons currently serves on the Boards of Directors for Rigel Pharmaceuticals, Vical Incorporated, Poinard Pharmaceuticals, and KaloBios Pharmaceuticals.  He was a former founding board member of Facet Biotech Corporation, which was sold to Abbott in April 2010. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and a Masters of Management from Northwestern University's J.L. Kellogg Graduate School of Management.

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental new drug application (sNDA) to expand the U.S. label for Qutenza for the management of pain due to HIV-associated neuropathy (HIV-AN) also known as HIV-distal sensory polyneuropathy (HIV-DSP).

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies and patient dosing is underway in a Phase 2 clinical trial in PHN patients.

The Company's early-stage pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated certain of these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements regarding expectations regarding the submission of the supplemental new drug application for label expansion of Qutenza and the timing of retirement and replacement of the Company's current President and Chief Executive Officer.  Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the further development of Qutenza for additional indications, including difficulties or delays in the submission of the sNDA for Qutenza; and delays in the search for a replacement President and Chief Executive Officer.  For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.

Stephen Ghiglieri

Executive Vice President, COO

and CFO

(650) 358-3310

The Ruth Group

Stephanie Carrington (investors)

(646) 536-7017

Jason Rando (media)

(646) 536-7025

SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX to Pursue Expanded U.S. Label for Qutenza® (capsaicin) 8% Patch in HIV-Associated Neuropathy
2. NeurogesX to Present at J.P. Morgan Health Care Conference
3. NeurogesX to Present at Piper Jaffray Health Care Conference
4. NeurogesX Reports Third Quarter 2009 Results
5. NeurogesX to Present at Two November Conferences
6. NeurogesX to Present at UBS Global Life Sciences Conference
7. NeurogesX to Present at Upcoming Fall Conferences
8. NeurogesX Appoints New Board Director and Audit Committee Chairman
9. NeurogesX Reports Second Quarter 2009 Results
10. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
11. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
Post Your Comments:
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... the remaining 11,000 post-share consolidation (or 1,100,000 pre-share ... "Series B Warrants") subject to the previously disclosed ... 23, 2015, which will result in the issuance ... to the issuance of such shares, there will ...
(Date:11/24/2015)... QC , Nov. 24, 2015 /CNW Telbec/ - ProMetic ... "Corporation") announced today that Mr. Pierre Laurin , President ... corporate presentation at the upcoming Piper Jaffray 27 th ... Palace Hotel, on December 1-2, 2015. st ... available for one-on-one meetings throughout the day. The presentation will ...
(Date:11/24/2015)... ... ... Whitehouse Laboratories is pleased to announce that it has completed construction on a new ... USP 61, USP 62 and USP 51 testing specific to raw materials and will ... performed by one supplier. Management has formally announced that the facility will ...
(Date:11/23/2015)... ... November 23, 2015 , ... Shimadzu ... of its Nexera UC Unified Chromatography system. The award from R&D magazine recognizes ... products of the year in the analytical and testing category. R&D Magazine chose ...
Breaking Biology Technology:
(Date:10/29/2015)...  Connected health pioneer, Joseph C. Kvedar , ... health and wellness, and the business opportunities that arise ... Internet of Healthy Things . Long before health ... Dr. Kvedar, vice president, Connected Health, Partners HealthCare, was ... care from the hospital or doctor,s office into the ...
(Date:10/29/2015)... YORK , Oct. 29, 2015 ... technology, announced a partnership with 2XU, a global ... to deliver a smart hat with advanced bio-sensing ... and other athletes to monitor key biometrics to ... the strategic partnership, the two companies will bring together ...
(Date:10/27/2015)... 27, 2015 Munich, Germany ... Mapping technology (ASGM) automatically maps data from mobile eye ... , so that they can be quantitatively analyzed ... Munich, Germany , October 28-29, 2015. SMI,s ... from mobile eye tracking videos created with SMI,s ...
Breaking Biology News(10 mins):